Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide (PTG-300) Clinical Development Program due to tumorigenicity.
FDA hold PTG-300: Protagonist Therapeutics Reports... - MPN Voice
FDA hold PTG-300
Written by
HFrank
To view profiles and participate in discussions please or .
1 Reply
•
« Belviq had similar rat tumor issues but allowed to complete trial & ultimately FDA approval - & this was for obesity
Highly unlikely for a deadly disease like polycythemia with no approved therapy will not have clinical hold removed on Rusfertide »
Not what you're looking for?
You may also like...
Rusfertide (for HCT Control)- FDA status
so long, an FDA hold a few years ago:
Oct 2021 \\"The FDA has removed the full clinical hold that...
FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera
preclinical and clinical research, and FDA approval. However, sometimes developers are sent back to...
Ruxolitinib filed to FDA for PV
I noticed that ruxolitinib has been filed to the FDA for treatment for PV. Looks like they will...
Blood cancers: New generation stem cell transplant significantly reduces complications for patients
USA, it's about to be accepted by the FDA for a Phase III Clinical Trial... Impressive results as...
Had to share him holding his little lantern
N-Acetylcysteine and symptom burden
Pegasys is applying for formal approval in MPN treatment
New meds for Myelofibrosis 
